Exocrine Pancreatic Insufficiency Treatment Market Share

North America Market Forecast

North America exocrine pancreatic insufficiency treatment market is expected to capture revenue share of over 56.1% by 2037. The presence of research organizations, the existence of advanced healthcare infrastructure and pharma companies, and increasing public investments in research and development activities are collectively contributing to the overall market growth. Both the U.S. and Canada are foreseen to offer lucrative opportunities to exocrine pancreatic insufficiency drug manufacturers owing to the rising prevalence of pancreatic conditions.

In the U.S., according to the American Cancer Society, around 66,440 individuals were diagnosed with pancreatic cancer in 2024. Furthermore, pancreatic cancer accounts for 3.0% of the overall cancer types. Such rising cancer incidence rates are fueling the demand for exocrine pancreatic insufficiency therapeutic solutions. The increasing awareness programs of gastrointestinal health are leading to early diagnosis and treatment of exocrine pancreatic insufficiency.

In Canada, the government’s supportive role in advancing its healthcare system is leading to increasing access to essential treatments including exocrine pancreatic insufficiency for a larger population. The increasing funding for research and development activities is also anticipated to drive the exocrine pancreatic insufficiency treatment market growth in the country. For instance, the Canadian Institutes of Health Research (CHIR) contributed around USD 352,57o to a project titled - Pancreatic Enzyme Replacement Therapy to Improve Quality of Life in Patients Undergoing Pancreatoduodenectomy: A Pilot Randomized Controlled Trial (PERQ-UP Pilot) with April 2021 completion date.

Asia Pacific Market Statistics

The Asia Pacific exocrine pancreatic insufficiency treatment market is forecast to increase at a robust pace during the study period. The increasing investments in the advancements of healthcare infrastructure, gut health awareness programs, and initiatives to mitigate cancer cases are augmenting the demand for advanced exocrine pancreatic insufficiency therapeutic solutions. China, India, Japan, and South Korea are offering win-win opportunities for exocrine pancreatic insufficiency drug producers.

In China, rising technological advancements in the field of diagnosis and treatment are set to drive overall exocrine pancreatic insufficiency treatment market growth in the coming years. The rising cases of pancreatic cancer and gastrointestinal disorders are increasing the consumption of exocrine pancreatic insufficiency medications. For instance, the National Center for Biotechnology Information (NCBI) reveals that the prevalence of gastrointestinal discomfort such as constipation is more than 30% in the elderly population.

In India, supportive government policies and initiatives to enhance national health are set to increase the sales of exocrine pancreatic insufficiency drugs in the coming years. For instance, in December 2024, the India Brand Equity Foundation (IBEF) revealed that the government is focusing on improving R&D in the pharma and MedTech sector by investing around USD 82.5 million. The country is also emerging as a global hub for generic drug production, which is leading to the easy availability of cost-effective pancreatic enzyme replacement therapies and drugs.